Keymed Biosciences Co.ltd

This study tests a biologic drug called CM512 in 120 people with chronic sinusitis and nasal polyps. Participants receive the drug as a shot under the skin. The goal is to see if it is safe and helps control symptoms. All participants have been in a previous CM512 study.

This early-stage study tests a new injection called CM336 in 30 adults with active Sjogren's syndrome. The main goal is to check safety and how the body handles the drug. Researchers will also look for signs that it helps control the disease. This is a Phase 1 trial, so it's one …

This Phase 2 study tests an injectable drug called CM313 in 106 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if CM313 is safe and can help control the disease by reducing kidney damage. Participants will receive either CM313 or…

This Phase 3 trial compares a new drug called CM336 against standard treatments for people with relapsed or refractory multiple myeloma who have already tried at least two prior therapies. About 280 participants will be randomly assigned to receive either CM336 or a standard-of-c…

Researchers are running a Phase 1 trial of CM583, an experimental biologic, in about 40 healthy adults aged 18 to 45. Participants receive a single injection under the skin of either CM583 or a placebo, with five increasing dose levels tested. The study tracks side effects, vital…